Keytru­da gets ac­cel­er­at­ed OK in HER2-pos­i­tive gas­tric can­cer; Twin­Strand gets $50M to hunt for 'nee­dles in a haystack'

King Keytru­da keeps rack­ing up ap­provals, earn­ing a new ac­cel­er­at­ed OK from the FDA on Wednes­day.

Reg­u­la­tors hand­ed down the ap­proval for HER2-pos­i­tive gas­tric can­cer in the first-line set­ting, in com­bi­na­tion with trastuzum­ab, flu­o­ropy­rim­i­dine- and plat­inum-based chemo. It’s yet an­oth­er thumbs-up for one of the best-sell­ing drugs in the world.

Wednes­day’s OK came on the ba­sis of a 264-pa­tient study with in­di­vid­u­als who had not pre­vi­ous­ly re­ceived treat­ment for their dis­ease. Pa­tients were ran­dom­ized 1-to-1 to re­ceive Keytru­da or place­bo every three weeks in ad­di­tion to the chemother­a­py reg­i­men.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.